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Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary
adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-
DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide,
thereby counteracting its effects. A Medline search for all of the available publications regarding the use of
temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors
that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of
the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with
multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and
demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus,
temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates
that there is an inverse correlation between levels of O6-methylguanine-DNA methyltransferase immunoexpression
and therapeutic response. Alternatively, high-level O6-methylguanine-DNA methyltransferase immunoexpression
correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms.
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INTRODUCTION
Patients with aggressive pituitary adenomas are difficult
to clinically manage. Frequently, these adenomas are large,
rapidly growing and invasive to their surroundings. These
tumors also present problems due to incomplete resection
and recurrence. Reoperation, pharmacological treatment
and radiotherapy are routinely employed, often in com-
bination. Nevertheless, many patients experience tumor
regrowth (1). Endocrinologically active adenomas, particu-
larly prolactin (PRL)- and growth hormone (GH)-producing
tumors, may become resistant to medical therapy, thus
requiring multiple resections. Radiation and conventional
chemotherapy are often employed in an attempt to achieve
local tumor control, but the results are often disappointing.
Pituitary carcinomas are rare and present parti-
cular diagnostic and therapeutic challenges. All of these
carcinomas are of large size, invasive and associated with
craniospinal and/or systemic metastases. Multiple treat-
ment approaches, including surgery, external beam radio-
therapy, radiosurgery, adjuvant pharmacological therapy
and various chemotherapeutic approaches, are palliative at
best, achieving only temporary effects (2,3). Progression of
the disease after the diagnosis of pituitary carcinoma is
variable but often inexorable. Approximately 75% of
patients with systemic metastasis die within 1 year of
documented spread (4).
Recent publications have reported the efficacy of temo-
zolomide for treating aggressive pituitary adenomas and
carcinomas (5–29). In this review, we discuss the indica-
tions, results and side effects of temozolomide therapy.
Temozolomide
Temozolomide is a second-generation alkylating che-
motherapeutic agent related to a series of imidazotetrazines
that were originally synthesized in 1987 (30). Orally
administered, it readily crosses the blood-brain barrier. At
physiological pH, it undergoes rapid conversion to methyl-
triazeno-imidazole-carboxamide (MTIC), the active agent. It
exerts its cytotoxic effects through methylation of DNA at
the O6 position of guanine (31), which then mispairs with
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thymine during the next cycle of DNA replication. The
sequence of mismatch-repair events lead to apoptosis.
Temozolomide is accepted as an essential component
of adjuvant therapy for the treatment of glioblastoma
multiforme and other tumors of the central nervous system
(32–34). Recent reports indicate its efficacy for treating
advanced-stage malignant neuroendocrine neoplasia (35),
melanoma (36,37), and colorectal carcinoma (38).
The standard therapeutic dose of temozolomide is 150–
200 mg/m2 for five of every 28 days (5/28). Depletion of O6-
methylguanine-DNA methyltransferase (MGMT) has been
proposed as a means of tumor response to temozolomide
(39). Experimental and clinical data have shown that the
temozolomide response is schedule-dependent and that
alternative dosing regimens may enhance its efficacy
(40,41). The anti-angiogenic effect of temozolomide can be
optimized by administering low doses of the drug on a
frequent or continuous schedule without extended interrup-
tions (i.e., ‘‘metronomic’’ chemotherapy). Temozolomide can
also be administered on a continuous, daily metronomic
schedule, thus achieving MGMT depletion and improving
the clinical response. This dose is generally 50 mg/m2/day
without interruption (28/28). Other temozolomide schedules
recommend administration every other week (7/14) or a 21-
consecutive-day regimen that is administered every 28 days
(21/28). Both are considered dose-dense regimens based on
the Norton-Simon model of cell proliferation, which states
that a dose of chemotherapy will have a fixed cell-kill rate
regardless of the size of the tumor (39). Thus, decreasing the
time interval between doses (i.e., increasing the dose density)
improves efficacy by minimizing the opportunity for cellular
regrowth between cycles (41). In these dose-dense regimens,
temozolomide is administered at a dose of 150 mg/m2/day
for 7 days every other week (7/14) or at a dose of 85–100 mg/
m2/day for 21 consecutive days (21/28) (40). In reported
pituitary cases, temozolomide was administered as mono-
therapy in all but three cases. The standard 5/28 regimenwas
used in almost all instances except in the series of Bush et al.
(23), in which a dose-dense, 21/28 schedule was used, and
one case progressed to carcinoma, which was then treated
using the metronomic 28/28 schedule (29). Temozolomide
absorption is only minimally affected by food. Furthermore,
no serious side effects have been reported. Common, non-
hematological adverse effects are present, including nausea,
vomiting, fatigue, headache and constipation, most of which
are mild to moderate in severity.
As previously stated, MGMT is a DNA repair protein that
reverses the effects of temozolomide therapy (42) by
removing alkylating adducts, thereby counteracting its
effects (43) and conferring resistance to the agent (44).
Low-level expression in a wide variety of human tumors is
thought to result from epigenetic silencing by hypermethy-
lation of the MGMT gene promoter (44,45). Low-level
MGMT expression is a predictive marker of a favorable
clinical outcome in patients with temozolomide-treated
glioblastomas (46–48). Herein, we extend this observation
to aggressive adenohypophysial tumors.
Pituitary adenomas
The first temozolomide-treated pituitary adenoma patient
was reported in 2006 (7,8). The tumor, which was
investigated using histological, immunohistochemical and
electron microscopic techniques, showed significant post-
therapeutic effects, including hemorrhage, necrosis, focal
fibrosis, reduced mitotic activity, Ki-67 labeling and,
surprisingly, neuronal transformation. MGMT immunoex-
pression was completely absent. Subsequently, the case of a
41-year-old patient with an aggressive silent subtype 2
corticotroph adenoma was reported (10). It showed no
morphological changes after temozolomide treatment. The
tumor cell nuclei were immunopositive for MGMT. Based
upon these results, it was suggested that MGMT immu-
noexpression may predict the responsiveness of temozolo-
mide therapy (10).
To the best of our knowledge, to date 30 cases of pituitary
adenoma have been treated with temozolomide (7-16,18-
20,22-26,28,29). Patient ages varied from 20 to 71 years
(mean: 51 years). Aside from one tumor that was inciden-
tally discovered in a patient with concomitant glioblastoma
multiforme, all tumors were morphologically studied. The
group included ten adrenocorticotropic hormone (ACTH)-
producing tumors, nine PRL-producing tumors, seven
clinically non-functioning adenomas, two silent ACTH
adenomas, and two GH-producing adenomas. The time
between clinical presentation and onset of temozolomide
treatment was between 2 and 23 years (mean: 10.7 years).
Twenty-six of the 30 tumors had been irradiated previously.
Aside from the incidentally discovered tumor in one
patient, all other patients had undergone at least one
operative procedure, the number ranging from 0 to 6
procedures (mean: 2.7). The response rate was 60% (18/30
patients). Debono et al. (11) reported the first case of a
pituitary adenoma associated with multiple endocrine
neoplasia type 1 (MEN1) that was treated with temozolo-
mide. The 47-year-old man had primary hyperparathyroid-
ism and a lesion at the head of the pancreas. Genetic
analysis confirmed MEN1. The dopamine-resistant, prolac-
tin-producing pituitary adenoma responded dramatically to
temozolomide, demonstrating clinical, biochemical, and
radiological improvements.
MGMT immunoexpression was documented in 23 of the
30 patients. A high level of labeling was seen in six
instances, an intermediate level in six instances, and a low
level in 11 instances. Only one of six patients with high
MGMT immunoexpression responded to temozolomide.
Two tumors with intermediate MGMT immunoexpression
did not respond, whereas nine of the 11 tumors with low-
level MGMT immunoexpression responded favorably.
Pituitary carcinomas
Pituitary carcinomas are difficult to manage given their
relentless growth and metastatic spread, despite the effects
of multimodality therapy. The latter includes repeated
surgeries, pharmacological manipulation, radiotherapy,
and conventional chemotherapy (3,49), including various
combinations of cis-platinum, etoposide and/or paclitaxel,
but these have failed to achieve favorable clinical responses
(2).
Initial reports of the successful use of temozolomide to
treat pituitary carcinomas appeared in 2006 (5,6). To date, 16
cases have been treated (5,6,13,16,17,21-23,25). The time
between disease presentation to temozolomide administra-
tion was 5–23 years (mean: 10.7 years). The group included
nine PRL-producing tumors, five ACTH-producing tumors,
three clinically non-functional tumors, and three silent
corticotroph carcinomas. Eleven of the 16 patients (69%)
experienced a clinical and radiological response to temozo-
lomide. Assessment of MGMT immunoexpression was only
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available in 11 patients; only one patient with high-level
immunoexpression responded to treatment.
Morphological changes
Morphological comparisons of pathology before and after
temozolomide treatment were performed in three cases: all
were patients with adenomas. One was a non-responder who
exhibited no changes (10) and two were responders (8,23)
whose tumors after treatment demonstrated hemorrhage,
necrosis, focal fibrosis, inflammatory infiltrates, fewer
mitoses, and a low Ki-67 labeling index, as well as neuronal
transformation. The latter is considered to be a metaplastic
phenomenon and has been observed in a variety of untreated
endocrine neoplasms, including GH cell adenomas (50).
DISCUSSION
Response to treatment
In patients who respond to temozolomide, three basic
patterns of radiographic changes are seen on MRI: tumor
necrosis and hemorrhage (7,8), cystic change (19), and
shrinkage (9,11-14). Such changes may be seen as early as
two months after the onset of treatment.
In the tumors that respond to temozolomide, the clinical
response is rapid and associated with prompt decreases in
chiasmatic compression and mass effects. In patients with
endocrine-active PRL- and ACTH-producing tumors, an
almost immediate reduction in plasma hormone levels
becomes apparent after commencement of therapy. Thus,
it is possible to quickly evaluate the treatment response.
MGMT immunoexpression and MGMT promoter
methylation
The inverse relationship between MGMT immunoexpres-
sion and temozolomide response was first reported in two
patients with aggressive pituitary adenomas (10). The
observation was subsequently confirmed by McCormack
et al. who assessed MGMT immunoreactivity in a PRL cell
carcinoma and an aggressive GH-producing adenoma (13).
In both studies, tumors with low-level MGMT immunoex-
pression demonstrated clinical and radiological responses to
temozolomide therapy. Other authors have reported similar
findings (51). Thus, the demonstration of MGMT immunor-
eactivity appears to be useful for predicting the response of
aggressive pituitary adenomas and carcinomas to temozo-
lomide treatment.
The reports of Kovacs et al. (10) and McCormack et al.
(13,51) underscore the inverse relationship between MGMT
immunoexpression and the efficacy of temozolomide
therapy, and this relationship has also been noted in high-
grade gliomas (46-48,52). Whereas the standard method for
evaluating MGMT status in gliomas is the identification of
promoter methylation (47), immunohistochemical detection
of MGMT expression is an attractive alternative. It repre-
sents an inexpensive, readily accessible technology that is
available to most laboratories (53,54). Whereas most reports
pertaining to gliomas and temozolomide therapy are based
on promoter methylation status, data relating to pituitary
neoplasms are based on MGMT immunoexpression (24,51).
Although several recent reports of aggressive pituitary
tumors that were successfully treated with temozolomide
have reported absent or low immunohistochemical expres-
sion of MGMT as a factor, one patient whose tumors
exhibited higher levels of MGMT staining also experienced
clinical improvement and tumor shrinkage following treat-
ment (23). It is of note that some tumors with no promoter
methylation also respond to therapy (22,23). These observa-
tions challenge the notion that MGMT promoter methyla-
tion is a reliable predictor of treatment response. Indeed,
two recent studies onMGMT promoter methylation and the
temozolomide response in eight aggressive adenomas and
seven pituitary carcinomas found no association between
promoter methylation status and response (22,23). Salehi et
al. (55) did not find a close correlation between MGMT
immunoexpression and MGMT promoter methylation in a
study on aggressive pituitary adenomas and carcinomas.
Thus, the utility of MGMT promoter methylation for the
selection of patients who might respond well to temozolo-
mide treatment remains controversial and an active focus of
further research. The problem is that many tumors possess
an admixture of MGMT immunopositive and immune-
negative cells. Obviously, in such instances, it is difficult to
predict overall the responsive to temozolomide.
To date, MGMT immunoexpression has been documen-
ted in 23 adenomas and 11 carcinomas. In 18 tumors,
MGMT labeling was low and correlated with a good
therapeutic response to temozolomide (14/18 cases). In
eight instances, MGMT staining was intermediate: five
tumors responded well and three did not. In eight patients
with high MGMT immunoexpression, only one responded
positively. Thus, tumors featuring low- and intermediate-
level MGMT immunoexpression (n= 26), when compared
with those with high MGMT immunoexpression (n= 8),
showed a good response to temozolomide in 19/26 (73%)
versus 1/8 (13%) cases (p= 0.0039; two-tailed Fisher’s exact
test).
Suggested indications for using temozolomide
treatment
Based on the published cases and the reported response
rates, temozolomide therapy can be recommended when
other options fail, particularly in the following instances: (1)
aggressive PRL-producing tumors that are resistant to
bromocriptine or cabergoline and continue to grow after
surgery and radiotherapy; (2) aggressive ACTH-producing
tumors, especially Crooke cell and Nelson syndrome
variants that cannot be cured by surgery and radiotherapy;
(3) recurrent, clinically non-functional tumors exhibiting
continued growth after repeated surgeries and radiother-
apy; (4) pituitary carcinomas.
Temozolomide has been documented as valuable for the
treatment of aggressive pituitary adenomas and carcinomas.
The clinical and radiological responses are encouraging:
60% of aggressive adenomas and 69% of pituitary carcino-
mas respond well to treatment. An inverse correlation exists
between MGMT immunoexpression and the therapeutic
response to temozolomide. Based upon our literature
review, a significant proportion of the adenohypophysial
tumors that are responsive to temozolomide show low-level
MGMT immunoexpression, whereas only one tumor show-
ing high-level immunoexpression was found to respond.
The use of immunohistochemistry for determining MGMT
immunoexpression appears to be a promising guide for
therapeutic decision-making (13,53). Obviously, all available
methods for assessing the likelihood of a positive temozo-
lomide response should be utilized. We feel strongly that
the determination of MGMT immunoreactivity is of clinical
value and that MGMT promoter methylation status should
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be determined as well. The molecular mechanisms that
affect MGMT expression remain to be fully elucidated.
Targeted modulation of MGMT may be used in patients
who may otherwise not respond to temozolomide therapy.
Future therapies that incorporate different dosing regimens
or other drugs may improve the tumor responsiveness.
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